A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

Inclusion Criteria: 1. Able and willing to provide a written informed consent； 2. Age ≥ 18 and ≤ 65 years old on the day of signing the informed consent ； 3. 0.9 mmol/L≤TG≤5.6 mmol/L； 4. Male or female； 5. Male subjects weigh ≥ 50 kg and \< 90 kg , female subjects weigh ≥ 45kg and \< 90 kg, and BMI is in the range of 19\~30 kg/m2 ；(including boundary values) Normal or abnormality such as vital signs, physical examination and laboratory examination have no clinical significance； 6. Subjects must be willing to use a highly effective method of contraception as deemed appropriate by the investigator throughout the study and for at least 6 months after the last study drug administration. Exclusion Criteria: 1. Those who suffer from any disease that affects drug absorption, distribution, metabolism, and excretion, or can reduce compliance determined by investigators; 2. Those who suffer from any clinical diseases such as as cardiovascular, liver, kidney, digestive tract, psychiatric, hematological, metabolic abnormalities; 3. A clinically significant history of drug allergies or atopic allergic diseases (asthma, urticaria, eczematous dermatitis); 4. Those with a history of malignant diseases; 5. Those with a history of involving clinical trials of any other drugs or medical devices within the previous 3 months of screening or planned to be conducted during the study period (excluding screening failures), or those who are still within 5 half-lives of the drugs before screening (whichever is longer); 6. Those who have experienced severe trauma or surgery within the previous 6 months, or plan to undergo surgery during the trial period; Serious infected individuals within the previous 3 months of screening; 7. Those who have used any drugs during the screening period or within 2 weeks before the baseline period; or those who are still in 5 half-lives of the drug at the time of screening (whichever is longer); 8. Serum LDL-C ≥ 4.1mmol/L; 9. Platelet count\<100 × 109/L; 10. Creatinine≥ upper limit of normal (ULN); 11. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyltransferase (GGT) ≥2×ULN, or total bilirubin ≥1.5×ULN; 12. During the screening period, human immunodeficiency virus antibodies (HIV-Ab), syphilis serological tests, hepatitis B virus surface antigen (HBs-Ag), or hepatitis C virus antibodies (HCV Ab) is positive; 13. Creatine kinase (CK) ≥ 3 ×ULN; 14. Thyroid stimulating hormone (TSH)\< limit of normal (LLN) or≥ 1.5 ×ULN; 15. Glomerular filtration rate (eGFR)\<60 mL/min/1.73m2; 16. Urine drug screening positive; 17. Those with a history of blood donation within the previous three months, severe blood loss (blood loss ≥ 400 mL), or who have received a blood transfusion within four weeks; 18. Those who have received the vaccine within the previous two weeks or plan to receive it during the trial process; 19. Those who started new physical exercise or made significantly changed their previous exercise activities within the previous 4 weeks, or who were unable to maintain basic stability in exercise during the study period; 20. Those who have made significant adjustments to their previous diet within the previous 4 weeks, or those whose diet cannot maintain basic stability during the study period; 21. Those who smoke an average of 5 or more cigarettes per day within the previous 4 weeks; 22. In the four weeks before screening, women's daily alcohol intake was more than 15 g, men's more than 25 g and more than twice a week, or the screening period and baseline period alcohol breath test (alcohol blood test can be replaced) was positive; 23. Those with a history of drug use or abuse; 24. Researchers, assistant researchers, research assistants, pharmacists, research coordinators, or other directly involved protocol implementers; 25. The researchers believe that subjects with any unfavorable factors to participate in this experiment.